Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10788939 | 0.83 | NPSR1 (0.38) | USP2CYP1A2 | |
| SCHEMBL2831752 | 0.82 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL1840485 | 0.82 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL1935525 | 0.82 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2192555 | 0.82 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2832088 | 0.82 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL6859632 | 0.81 | CYP2C19 (0.47) | CYP2C19 | |
| Methane SCHEMBL2480640 | 0.80 | TSHR (0.34) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11579187 | 0.80 | TSHR (0.34) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL1020071 | 0.79 | ALDH1A1 (0.32) | TSHRCYP2C19ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518080-B1 | Antibiotic peptides | AMP THERAPEUTICS GMBH (DE) | 2016-05-18 | — | — | EP | claimed |
| EP-2170928-B1 | ANTIBIOTIC PEPTIDES | AMP THERAPEUTICS GMBH (DE) | 2013-07-03 | — | — | EP | claimed |
| EP-2518080-A2 | Antibiotic peptides | AMP-Therapeutics GmbH & Co. KG (DE) | 2012-10-31 | — | — | EP | claimed |
| CN-101801995-A | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2010-08-11 | — | — | CN | claimed |
| EP-1688126-B1 | GLYCYLGLYCINE AS PARAKERATOSIS INHIBITOR | SHISEIDO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8586638-B2 | Parakeratosis inhibitor and skin preparation for external use | SHISEIDO COMPANY, LTD (JP) | 2013-11-19 | — | — | US | disclosed |
| CN-101801995-B | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY, LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2491981-A2 | Parakeratosis inhibitor and external composition for skin | SHISEIDO COMPANY LIMITED (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491980-A2 | Parakeratosis inhibitor and skin preparation for external use | SHISEIDO COMPANY LIMITED (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120053243-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-101801995-A | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2010-08-11 | — | — | CN | disclosed |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | SHISEIDO COMPANY LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1688126-A1 | PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053243-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | CUTA, HPN, DNPEP | TSHR 4754/4885CYP2C19 4048/4885USP2 1779/4885 |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | CUTA, HPN, PRSS1 | TSHR 4725/4885CYP2C19 3760/4885USP2 2130/4885 |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | CUTA, HPN, DNPEP | TSHR 4754/4885CYP2C19 4048/4885USP2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.